Loading...

Clinuvel Pharmaceuticals

DB:UR9
Snowflake Description

Flawless balance sheet with outstanding track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UR9
DB
A$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Clinuvel Pharmaceuticals has significant price volatility in the past 3 months.
UR9 Share Price and Events
7 Day Returns
-10.2%
DB:UR9
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
90%
DB:UR9
-7.4%
DE Biotechs
-5.6%
DE Market
UR9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Clinuvel Pharmaceuticals (UR9) -10.2% -11.1% 3.1% 90% 392.5% 1284.3%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • UR9 outperformed the Biotechs industry which returned -7.4% over the past year.
  • UR9 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
UR9
Industry
5yr Volatility vs Market

Value

 Is Clinuvel Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Clinuvel Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Clinuvel Pharmaceuticals.

DB:UR9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:UR9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 30%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:UR9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Clinuvel Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:UR9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 8%)
2019 20.64 Est @ 40.32% 19.11
2020 26.48 Est @ 28.29% 22.71
2021 31.75 Est @ 19.87% 25.20
2022 36.19 Est @ 13.98% 26.60
2023 39.75 Est @ 9.85% 27.06
2024 42.52 Est @ 6.97% 26.80
2025 44.62 Est @ 4.95% 26.04
2026 46.20 Est @ 3.53% 24.97
2027 47.37 Est @ 2.54% 23.70
2028 48.25 Est @ 1.85% 22.35
Present value of next 10 years cash flows A$244.55
DB:UR9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$48.25 × (1 + 0.23%) ÷ (8% – 0.23%)
A$622.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$622.47 ÷ (1 + 8%)10
A$288.42
DB:UR9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$244.55 + A$288.42
A$532.97
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$532.97 / 48.96
A$10.89
DB:UR9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:UR9 represents 0.64416x of ASX:CUV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.64416x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (AUD) x Listing Adjustment Factor
= A$ 10.89 x 0.64416
€7.01
Value per share (EUR) From above. €7.01
Current discount Discount to share price of €14.12
= -1 x (€14.12 - €7.01) / €7.01
-101.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Clinuvel Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Clinuvel Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Clinuvel Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UR9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.33
ASX:CUV Share Price ** ASX (2019-04-24) in AUD A$21.92
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Clinuvel Pharmaceuticals.

DB:UR9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CUV Share Price ÷ EPS (both in AUD)

= 21.92 ÷ 0.33

66.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clinuvel Pharmaceuticals is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Clinuvel Pharmaceuticals is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Clinuvel Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:UR9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 66.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
1.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Clinuvel Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Clinuvel Pharmaceuticals's assets?
Raw Data
DB:UR9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.90
ASX:CUV Share Price * ASX (2019-04-24) in AUD A$21.92
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:UR9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CUV Share Price ÷ Book Value per Share (both in AUD)

= 21.92 ÷ 0.90

24.32x

* Primary Listing of Clinuvel Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clinuvel Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Clinuvel Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Clinuvel Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Clinuvel Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Clinuvel Pharmaceuticals, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Clinuvel Pharmaceuticals expected to grow at an attractive rate?
  • Clinuvel Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Clinuvel Pharmaceuticals's earnings growth is positive but not above the Germany market average.
  • Unable to compare Clinuvel Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:UR9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UR9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 1.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UR9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UR9 Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:UR9 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 27 15 16
2018-09-30 26 13 15
2018-06-30 25 12 13
2018-03-31 21 10 10
2017-12-31 17 8 6
2017-09-30 17 9 7
2017-06-30 17 10 7
2017-03-31 14 7 5
2016-12-31 12 4 3
2016-09-30 9 -1 0
2016-06-30 7 -5 -3
2016-03-31 5 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Clinuvel Pharmaceuticals's earnings are expected to grow by 1.7% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Clinuvel Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UR9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Clinuvel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UR9 Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:UR9 Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.33
2018-09-30 0.30
2018-06-30 0.28
2018-03-31 0.20
2017-12-31 0.13
2017-09-30 0.14
2017-06-30 0.15
2017-03-31 0.10
2016-12-31 0.06
2016-09-30 0.00
2016-06-30 -0.07
2016-03-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Clinuvel Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Clinuvel Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Clinuvel Pharmaceuticals has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Clinuvel Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Clinuvel Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Clinuvel Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Clinuvel Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (161.2% vs 67.5%)
  • Clinuvel Pharmaceuticals's earnings growth has exceeded the Europe Biotechs industry average in the past year (161.2% vs 18.2%).
Earnings and Revenue History
Clinuvel Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Clinuvel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UR9 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 27.40 15.86 5.99 6.19
2018-09-30 26.44 14.54 6.18 6.09
2018-06-30 25.49 13.22 6.36 5.99
2018-03-31 21.22 9.65 6.16 5.38
2017-12-31 16.95 6.07 5.96 4.77
2017-09-30 16.86 6.63 5.63 4.41
2017-06-30 16.77 7.18 5.30 4.05
2017-03-31 14.42 4.93 4.77 3.79
2016-12-31 12.08 2.68 4.24 3.52
2016-09-30 9.45 -0.22 4.47 3.63
2016-06-30 6.82 -3.12 4.70 3.73
2016-03-31 5.35 -4.71 3.11 3.42
2015-12-31 3.88 -6.30 1.51 3.10
2015-09-30 3.60 -8.35 3.57 2.85
2015-06-30 3.32 -10.40 5.63 2.60
2015-03-31 3.10 -10.03 7.53 2.84
2014-12-31 2.89 -9.66 9.43 3.08
2014-09-30 2.78 -7.59 7.15 3.17
2014-06-30 2.66 -5.53 4.86 3.26
2014-03-31 2.51 -5.63 5.11 3.12
2013-12-31 2.35 -5.72 5.35 2.99
2013-09-30 2.42 -6.26 5.23 3.74
2013-06-30 2.49 -6.80 5.12 4.49
2013-03-31 2.08 -7.35 4.87 4.85
2012-12-31 1.67 -7.90 4.63 5.21
2012-09-30 1.20 -8.83 5.04 5.30
2012-06-30 0.72 -9.77 5.46 5.39

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Clinuvel Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Clinuvel Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Clinuvel Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Clinuvel Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Clinuvel Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Clinuvel Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Clinuvel Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Clinuvel Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Clinuvel Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Clinuvel Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Clinuvel Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Clinuvel Pharmaceuticals Company Filings, last reported 3 months ago.

DB:UR9 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 43.13 0.00 42.83
2018-09-30 43.13 0.00 42.83
2018-06-30 39.42 0.00 36.20
2018-03-31 39.42 0.00 36.20
2017-12-31 27.37 0.00 27.94
2017-09-30 27.37 0.00 27.94
2017-06-30 25.44 0.00 23.75
2017-03-31 25.44 0.00 23.75
2016-12-31 20.55 0.00 19.55
2016-09-30 20.55 0.00 19.55
2016-06-30 17.83 0.00 13.84
2016-03-31 17.83 0.00 13.84
2015-12-31 8.79 0.00 7.50
2015-09-30 8.79 0.00 7.50
2015-06-30 11.21 0.00 10.57
2015-03-31 11.21 0.00 10.57
2014-12-31 12.78 0.00 11.98
2014-09-30 12.78 0.00 11.98
2014-06-30 15.43 0.00 14.63
2014-03-31 15.43 0.00 14.63
2013-12-31 10.86 0.00 9.75
2013-09-30 10.86 0.00 9.75
2013-06-30 13.84 0.00 12.57
2013-03-31 13.84 0.00 12.57
2012-12-31 9.75 0.00 10.11
2012-09-30 9.75 0.00 10.11
2012-06-30 13.64 0.00 13.17
  • Clinuvel Pharmaceuticals has no debt.
  • Clinuvel Pharmaceuticals has not taken on any debt in the past 5 years.
  • Clinuvel Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Clinuvel Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Clinuvel Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Clinuvel Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.09%
Current annual income from Clinuvel Pharmaceuticals dividends.
If you bought €2,000 of Clinuvel Pharmaceuticals shares you are expected to receive €2 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Clinuvel Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • Clinuvel Pharmaceuticals's dividend is below the markets top 25% of dividend payers in Germany (3.7%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UR9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UR9 Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
DB:UR9 Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2018-08-29 0.020 0.099

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clinuvel Pharmaceuticals is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Clinuvel Pharmaceuticals is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Clinuvel Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Clinuvel Pharmaceuticals's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Clinuvel Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Clinuvel Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Clinuvel Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Clinuvel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philippe Wolgen
COMPENSATION A$2,288,277
AGE 55
TENURE AS CEO 13.4 years
CEO Bio

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 2005 to lead the corporate turnaround of the Group. Dr. Wolgen managed a pharmaceutical company, part of the MOG Group in The Netherlands and was involved in taking craniofacial medical devices to markets. He has been a Director at Clinuvel Pharmaceuticals Limited since October 1, 2005. He holds an MBA from Columbia University NY and the London Business School. Trained as a surgeon Dr. Wolgen holds an MD from the University of Utrecht, the Netherlands.

CEO Compensation
  • Philippe's compensation has increased by more than 20% in the past year.
  • Philippe's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Clinuvel Pharmaceuticals management team in years:

13.3
Average Tenure
  • The average tenure for the Clinuvel Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Philippe Wolgen

TITLE
CEO, MD & Director
COMPENSATION
A$2M
AGE
55
TENURE
13.4 yrs

Darren Keamy

TITLE
CFO & Company Secretary
COMPENSATION
A$350K
AGE
45
TENURE
13.3 yrs

Dennis Wright

TITLE
Acting Chief Scientific Officer
COMPENSATION
A$298K
TENURE
6.6 yrs

Lachlan Hay

TITLE
General Manager of Europe
Board of Directors Tenure

Average tenure and age of the Clinuvel Pharmaceuticals board of directors in years:

11.3
Average Tenure
66
Average Age
  • The average tenure for the Clinuvel Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Stan McLiesh

TITLE
Non-Executive Chairman
COMPENSATION
A$118K
AGE
81
TENURE
11.3 yrs

Philippe Wolgen

TITLE
CEO, MD & Director
COMPENSATION
A$2M
AGE
55
TENURE
13.5 yrs

Willem Blijdorp

TITLE
Non-Executive Director
COMPENSATION
A$74K
AGE
66
TENURE
4.3 yrs

Karen Agersborg

TITLE
Non-Executive Director
COMPENSATION
A$28K
TENURE
1.3 yrs

Brenda Shanahan

TITLE
Non-Executive Director
COMPENSATION
A$88K
TENURE
12.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Oct 18 Sell Lagoda Investment Management, L.P. Company 11. Jul 18 01. Oct 18 -410,529 €14.05 €-5,766,869
03. Oct 18 Buy Lagoda Investment Management, L.P. Company 09. Jul 18 01. Aug 18 7,602 €7.58 €57,644
11. Sep 18 Sell FIL Limited Company 03. Sep 18 07. Sep 18 -213,314 €9.41 €-1,980,228
04. Sep 18 Sell FIL Limited Company 16. Jul 18 31. Aug 18 -482,956 €8.81 €-4,254,204
17. Jul 18 Sell FIL Limited Company 15. May 18 13. Jul 18 -544,034 €8.14 €0
17. Jul 18 Buy FIL Limited Company 17. May 18 17. May 18 5,328 €7.96 €42,430
06. Jul 18 Buy Willem Blijdorp Individual 02. Jul 18 02. Jul 18 1,359,973 €6.31 €8,581,706
04. Jul 18 Sell Lagoda Investment Management, L.P. Company 16. May 18 02. Jul 18 -1,372,243 €8.31 €-8,678,458
04. Jul 18 Buy Lagoda Investment Management, L.P. Company 21. May 18 27. Jun 18 2,500 €8.56 €20,058
17. May 18 Sell Lagoda Investment Management, L.P. Company 26. Oct 17 15. May 18 -1,098,939 €8.41 €-9,241,782
16. May 18 Sell FIL Limited Company 27. Apr 18 14. May 18 -483,694 €8.26 €-3,994,308
30. Apr 18 Sell FIL Limited Company 01. Jun 16 26. Apr 18 -860,034 €7.49 €-6,440,315
X
Management checks
We assess Clinuvel Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Clinuvel Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited is headquartered in Melbourne, Australia.

Details
Name: Clinuvel Pharmaceuticals Limited
UR9
Exchange: DB
Founded:
A$673,445,787
48,960,633
Website: http://www.clinuvel.com
Address: Clinuvel Pharmaceuticals Limited
15 Queen Street,
Level 6,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CUV Ordinary Shares Australian Securities Exchange AU AUD 13. Feb 2001
OTCPK CLVL.F Ordinary Shares Pink Sheets LLC US USD 13. Feb 2001
DB UR9 Ordinary Shares Deutsche Boerse AG DE EUR 13. Feb 2001
MUN UR9 Ordinary Shares Boerse Muenchen DE EUR 13. Feb 2001
CHIA CUV Ordinary Shares Chi-X Australia AU AUD 13. Feb 2001
OTCPK CLVL.Y SPON ADR Pink Sheets LLC US USD 04. May 2004
Number of employees
Current staff
Staff numbers
0
Clinuvel Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:33
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2018/08/29
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.